| | | 上海润达医疗科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、可转债发行上市概况 在 2026 年 1 月 1 日至 2026 年 3 月 31 日期间，共有人民币 319,000 元的"润 达转债"已转换成公司股份，转股数量为 24,590 股。截至 2026 年 3 月 31 日， 累计人民币 316,162,000 元的"润达转债"转换成公司股份，占可转债发行总量 57.4840%，累计转股数量为 24,169,262 股，占可转债转股前公司已发行股份总额 的 4.1705%。 截至 2026 年 3 月 31 日，尚未转股的"润达转债"金额为人民币 233,838,000 元，占可转债发行总量的 42.5160%。 三、股本变动情况 （三）根据有关规定和《上海润达医疗科技股份有限公司公开发行可转换公 司债券募集说明书》的约定，公司本次发行的"润达转债"自 2020 年 12 月 23 日 起可转换为公司股份，初始转股价格为 13.36 元/股 ...

关于调整公司 2025 年度担保预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 杭州怡丹生物技术有限公司 | | --- | --- | --- | | | 本次担保金额 | 万元 23,000 | | 担保对 | 实际为其提供的担保余额 | 万元 19,300 | | 象一 | 是否在前期预计额度内 | □是 □否 不适用：本次为担保预计调整 | | | 本次担保是否有反担保 | □是 □否 不适用：本次为担保预计调整 | | 担保对 象二 | 被担保人名称 | 北京东南悦达医疗器械有限公司 | | | 本次担保金额 | 万元 8,000 | | | 实际为其提供的担保余额 | 0.00 万元 | | | 是否在前期预计额度内 | □是 □否 不适用：本次为担保预计调整 | | | 本次担保是否有反担保 | □是 □否 | | | | 不适用：本次为担保预计调整 | 对控股子公司杭州怡丹生物技术有限公司（以下简称"杭州怡丹"）的担保 预计金额由 ...

| 股东名称 | 朱文怡 | | --- | --- | | 本次解质股份 | 10,540,000 | | 占其所持股份比例 | 37.68% | | 占公司总股本比例 | 1.75% | | 解质时间 | 2026 年 3 月 23 日 | | 持股数量 | 27,970,309 | | 持股比例 | 4.63% | | 剩余被质押股份数量 | 0 | | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-018 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 股东股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次股份被解质情况 上海润达医疗科技股份有限公司（以下简称"公司"）于今日接到股东朱文 怡女士通知，获悉其原质押给中信建投证券股份有限公司的股份解除质押，具体 如下： 朱文怡女士持有公司股份 27,970,309 股，占公司总股本的 4.63%。本次将原 质押给中信 ...

Group 1 - The report highlights a shift in China's innovative drug development from "fast-following" to "innovation-leading," potentially reshaping the global new drug development landscape. Key emerging technology platforms include molecular glue, small nucleic acids, and in vivo CAR-T, with Chinese companies making significant investments in these areas [3][4]. - Molecular glue offers a new paradigm for targeting "undruggable" targets, with significant potential in the PAN-RAS space. Companies to watch include Heng Rui Medicine, Jinfang Medicine, Yuandong Biology, and Betta Pharmaceuticals [3]. - Small nucleic acids are expanding from rare diseases to chronic conditions, with numerous companies involved in hypertension, dyslipidemia, weight loss, MASH, and CNS diseases. Notable companies include Heng Rui Medicine, Shiyao Group, and Innovent Biologics [3]. - In vivo CAR-T technology is cost-effective and enhances accessibility, showing promise in oncology and autoimmune diseases. Key players include Yunding Xinyao and Kexi Pharmaceuticals [3]. - The integration of AI in healthcare and drug development is accelerating, with companies like Runda Medical and Kangzhong Medical leading the way [3]. Group 2 - The report reviews the performance of the pharmaceutical sector in 2025, noting a cumulative increase of 11.9% in the pharmaceutical index, while the broader market rose by 30.2%, indicating a relative underperformance of 18.3% [8][14]. - The valuation of the pharmaceutical sector has slightly improved, with the PE (TTM) ratio rising from 29.8x at the beginning of 2025 to 36.2x by year-end, while the broader market's PE increased from 28.6x to 39.5x [14]. - The pharmaceutical sector's revenue for the first three quarters of 2025 reached CNY 18,544 billion, with a year-on-year decline of 0.4%, and net profit attributable to shareholders was CNY 1,407 billion, down 0.8% year-on-year [17][22]. Group 3 - The report indicates that the number of IND (Investigational New Drug) applications for innovative drugs in 2025 reached 3,626, marking a year-on-year growth of 10.4%. The number of NDA (New Drug Application) submissions also increased, with 83 for chemical drugs and 271 for therapeutic biological products [31][29]. - The report emphasizes the growing trend of molecular glue technology, particularly in targeting RAS mutations, which are prevalent in approximately 30% of malignancies. The representative drug Daraxonrasib has shown significant clinical efficacy [53][50]. - The report notes an increase in collaboration and licensing activities in the molecular glue sector, with major pharmaceutical companies engaging in high-value transactions, indicating a robust interest in this innovative technology [54][56].

Investment Rating - The report maintains an "Optimistic" rating for the AI4S industry, highlighting its role as a key multiplier for new productive forces and future industry development, supported by policy backing and technological advancements [5][4]. Core Insights - AI4S (AI for Science) is positioned as the first priority in the "Artificial Intelligence+" action plan, emphasizing its significance in accelerating scientific discovery and enhancing research efficiency across various foundational disciplines [12][11]. - The report outlines a clear investment strategy along the technology chain, focusing on core segments with high potential, including upstream AI4S-specific computing power, midstream cross-scale computing, and downstream innovative materials and pharmaceuticals [5][4]. - The report emphasizes the importance of understanding the technology chain and ROI of AI4S, which can lead to significant cost savings and efficiency improvements in research and development [18][5]. Summary by Sections 1. Top-Down Analysis of AI4S - AI4S is recognized as a critical accelerator for new productive forces and future industries, with its integration into various foundational scientific research areas [11][12]. - The report discusses the importance of AI4S in international competitive fields, suggesting its application can enhance research capabilities in key technological areas [17][11]. 2. Bottom-Up Analysis of AI4S Technology Chain and ROI - The report details a six-layer breakdown of the AI4S technology chain, spanning micro, meso, and macro levels, each with specific outputs and implications for investment [18][19]. - It provides analogies to help investors understand the complex technology, comparing AI4S processes to stock investment decision-making and deep learning image recognition [33][36]. 3. Industry Chain: Technical Segmentation and Business Models - The AI4S industry chain is segmented into upstream (computing power and databases), midstream (cross-scale computing and experimental robotics), and downstream (materials and pharmaceuticals) applications [7][4]. - The report highlights the importance of identifying genuine AI4S companies based on their technological capabilities and data sources [7][6]. 4. Participants in the AI4S Market - The report lists potential investment targets in the secondary market, including companies like JingTai Holdings and ZhiTe New Materials, which are positioned at the intersection of AI4S and their respective industries [5][4]. - It also identifies key players in the primary market, emphasizing their potential for capital market entry and growth [5][4].

上述被担保人非上市公司关联人。 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-017 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 资产负债率为 | 70%以上的全资及控股子公司 | | | | | --- | --- | --- | --- | --- | | 担保对 | 被担保人名称 | | 杭州润达医疗管理有限公司 | | | | 本次担保金额 5,758 | 万元 | | | | 象一 | 实际为其提供的担保余额 | 159,106.29 | 万元 | | | | 是否在前期预计额度内 是 | | □否 | □不适用：_________ | | | 本次担保是否有反担保 □是 | | 否 | □不适用：_________ | | 担保对 | 被担保人名称 | | | 上海润 ...

Investment Rating - The report maintains an "optimistic" rating for the AI4S industry, highlighting its role as a key multiplier for new productive forces and future industry development, supported by policy backing and technological penetration [6]. Core Insights - AI4S is positioned as the first priority in the "Artificial Intelligence+" action plan, emphasizing its significance in accelerating scientific discovery and enhancing research and development efficiency across various fields [15][17]. - The report outlines a clear investment strategy along the technology chain, focusing on core segments with high potential in AI4S, including upstream dedicated computing power, midstream cross-scale computing, and downstream innovative materials and drugs [6][8]. - The report emphasizes the importance of understanding the technology chain and ROI of AI4S, which can lead to significant cost savings and efficiency improvements in research and development [6][23]. Summary by Sections 1. Overview of AI4S - AI4S is recognized as a foundational technology that permeates various basic scientific research fields and is crucial for international competitive domains [14][19]. - The report categorizes AI4S into narrow and broad definitions, with narrow AI4S focusing on specific applications in pharmaceuticals and materials, while broad AI4S encompasses a wider range of scientific disciplines [19][44]. 2. Technology Chain and ROI - The report details a six-layer breakdown of the technology chain from micro to macro levels, illustrating how AI can achieve a "structure-performance" mapping [23][24]. - It provides analogies to help investors understand the complex technical aspects of AI4S, comparing it to investment decision-making processes and deep learning image recognition [39][43]. 3. Industry Chain Analysis - The AI4S industry chain is segmented into upstream, midstream, and downstream components, focusing on dedicated computing power, cross-scale computing platforms, and applications in materials and pharmaceuticals [8][21]. - The report identifies key players in both secondary and primary markets, highlighting companies with significant potential for growth and innovation in the AI4S space [6][21]. 4. Market Participants - The report lists various companies in the secondary market, such as JingTai Holdings and Ningde Times, which are positioned at the intersection of AI4S and their respective industries [6][21]. - It also mentions primary market representatives like SiLang Technology and DeepForce Technology, indicating their potential for capital market entry [6][21].

Group 1 - The core viewpoint of the news is that RunDa Medical has experienced fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks [1][2][3] Group 2 - On February 25, RunDa Medical's stock rose by 3.79%, with a trading volume of 700 million yuan. The financing buy-in amount for the day was 67.07 million yuan, while the financing repayment was 58.99 million yuan, resulting in a net financing buy-in of 8.07 million yuan [1] - As of February 25, the total balance of margin trading for RunDa Medical was 629 million yuan, with the financing balance accounting for 6.31% of the circulating market value, indicating a high level compared to the past year [1] - The company reported a total revenue of 5.268 billion yuan for the period from January to September 2025, reflecting a year-on-year decrease of 14.70%, and a net profit attributable to shareholders of -163 million yuan, a significant decline of 422.64% [2] - RunDa Medical has distributed a total of 373 million yuan in dividends since its A-share listing, with 165 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for RunDa Medical was 64,800, a decrease of 1.05% from the previous period, while the average circulating shares per person increased by 1.06% to 9,317 shares [2][3]

Core Insights - The report from Zhonghang Securities highlights the ongoing integration of AI products and services in the healthcare sector, focusing on areas such as medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics. AI is evolving from a "technical assistant" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the medical industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] International Developments - In the international arena, significant advancements are noted in AI medical imaging diagnostics and AI-assisted drug discovery. AI systems for abdominal CT multi-disease triage and fetal abnormal ultrasound imaging have received FDA approval, indicating a shift from single-disease assistance to comprehensive triage and decision support systems. Collaborations between pharmaceutical companies and AI tech firms are enhancing cancer early screening capabilities, potentially increasing cancer diagnosis rates and accessibility to treatment drugs. Additionally, AI imaging diagnostics for stroke have gained recognition at top academic conferences, reflecting the growing acceptance of AI technology in clinical and research communities [1] - In drug discovery, international pharmaceutical companies are partnering with AI tech firms to accelerate new drug development. The world's first fully AI-designed antibody drug, GB-0895, has entered Phase III clinical trials, marking a significant breakthrough from concept to clinical practice. Google has also launched two open-source AI models for medical applications, enhancing capabilities in multi-modal analysis and voice interaction [1] Domestic Developments - Domestically, the value of AI in early drug development is being clinically validated, with companies like InSilico Medicine receiving FDA approval for new drug applications via AI platforms. AI-assisted diagnosis is expanding into various medical scenarios, with recent approvals for AI software in cervical cell digital pathology and accelerated AI healthcare initiatives from leading in vitro diagnostic companies. The emergence of large AI models in China is also noteworthy, with local teams publishing evaluation standards in international journals, showcasing the competitive edge of Chinese medical AI models [2] - Significant advancements are being made in AI imaging, surgical robots, and brain-computer interfaces, with AI accelerating the development of medicine and drug research. Recent policies related to AI in healthcare are being actively discussed, focusing on the reliability and compliance of AI-assisted diagnosis and the use of medical data [2] Investment Opportunities - Key investment opportunities identified include: 1) AI drug development: companies like Crystal Technology, Hongbo Pharmaceutical, Chengdu XianDao, and InSilico Medicine 2) AI medical imaging and assisted diagnosis: companies such as United Imaging Healthcare and Wandong Medical 3) Medical information technology and smart hospitals: firms like Jiahe Meikang, Chuangye Huikang, Donghua Software, and Weining Health 4) Internet healthcare and health platforms: including JD Health, Alibaba Health, and Ping An Good Doctor 5) Precision medicine and AI-driven medical services: companies like Kingmed Diagnostics, Runda Medical, and Meinian Health 6) Technology/data platform enterprises: such as iFlytek Medical and Yidu Technology [4] AI Medical Core Themes - The core themes in AI healthcare investment revolve around addressing industry pain points. AI-assisted diagnosis enhances diagnostic efficiency and consistency, supporting grassroots healthcare with clear cost-reduction and efficiency benefits. In cancer early screening, companion diagnostics, and efficacy prediction, AI contributes to achieving precision medicine. The maturity of AI applications varies, with AI medical imaging evolving from single-disease assistance to multi-disease integration and comprehensive management. AI-assisted drug discovery is transitioning from early discovery to clinical validation, necessitating attention to platform technology validation and deep collaborations with top pharmaceutical companies [3] - The development of large medical AI models and multi-modal AI, capable of processing diverse medical data, is crucial. The focus should be on the accuracy of these models in specialized fields, their integration with existing hospital information systems, and their potential to build an ecosystem as foundational "medical intelligent agents" [3]

Core Viewpoint - The announcement details a share reduction plan by major shareholders and executives of Shanghai RunDa Medical Technology Co., Ltd, indicating a planned divestment of shares within a specified timeframe [3][4]. Group 1: Shareholder and Executive Holdings - As of the announcement date, executive Liu Hui holds 31,528,771 shares, representing 5.22% of the total share capital of the company [2]. - Shareholder Zhu Wenyi holds 28,839,409 shares, accounting for 4.78% of the total share capital [2]. Group 2: Reduction Plan Details - Zhu Wenyi and Liu Hui plan to reduce their holdings through block trades or centralized bidding within three months after 15 trading days from the announcement date [3]. - The total number of shares to be reduced through centralized bidding will not exceed 1% of the total share capital, while through block trades, it will not exceed 2% [4]. Group 3: Compliance and Conditions - The reduction plan will comply with relevant laws and regulations, and any corporate actions such as dividends or stock splits during the reduction period will adjust the number of shares to be reduced accordingly [4]. - The shareholders have committed to adhere to previous promises regarding shareholding and reduction conditions, ensuring that the reduction does not affect the control of the company [6].